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IntegrationGene expression data and genotype variation data are now capable of providing genome-wide patterns
across many different clinical conditions. However, the separate analysis of these data has limitations in
elucidating the complex network of gene interactions underlying complex traits, such as common human
diseases. More information about the identity of key driver genes of common diseases comes from
integrating these two heterogeneous types of data. We developed a two-step procedure to characterize
complex diseases by integrating genotype variation data and gene expression data. The ﬁrst step elucidates
the causal relationship among genetic variation, gene expression level, and disease. Based on the causal
relationship determined at the ﬁrst step, the second step identiﬁes signiﬁcant gene expression traits whose
effects on disease status or whose responses to disease status are modiﬁed by the speciﬁc genotype variation.
For the selected signiﬁcant genes, a pathway enrichment analysis can be performed to identify the genetic
mechanism of a complex disease. The proposed two-step procedure was shown to be an effective method for
integrating three different levels of data, i.e., genotype variation, gene expression and disease status. By
applying the proposed procedure to a chronic fatigue syndrome (CFS) dataset, we identiﬁed a list of potential
causal genes for CFS, and found an evidence for difference in genetic mechanisms of the etiology between
CFS without ‘a major depressive disorder with melancholic features’ (CFS) and CFS with ‘a major depressive
disorder with melancholic features’ (CFS-MDD/m). Especially, the SNPs within NR3C1 gene were shown to
differently inﬂuence the susceptibility of developing CFS and CFS-MDD/m through integrative action with
gene expression levels.© 2009 Elsevier Inc. All rights reserved.IntroductionIn the past few years, high through-put technologies, such as gene
expression microarrays and genotyping techniques, have provided
efﬁcient ways to measure gene expression levels and genotype
variation on genome-wide scale. Various approaches have been
proposed to analyze gene expression data and genotype variation
data, and hence to discover a complex network of biochemical process
underlying living systems [1] and common human diseases [2,3], and
candidate genes [4]. In the analysis of gene expression data, for
example, the identiﬁcation of differentially expressed genes between
two groups has been of great interest, and has been conducted via
various statistical tests [5–7]. In analyzing genotype variation data,
logistic regression has been commonly used to model the relationship
between binary clinical outcomes and discrete predictors, such as
genotypes [8].
Despite the availability of different levels of genome-wide data,
most studies have been based on a separate analysis of single-levelo71@snu.ac.kr (S. Cho),
r (T. Park).
ll rights reserved.data to unravel complex biological mechanisms, such as complex
human diseases. Complex diseases can be explained at different levels
of biological mechanisms, including DNA, gene expression and
phenotype levels. While there is a separate mechanism at each
level, the mechanisms at different levels are closely related to each
other in initiating and inﬂuencing complex diseases. Furthermore,
most common human diseases have complex etiology involving
action of many genes as well as dynamic gene–environment
interactions. Therefore, separate analyses of single-level data have a
limitation in identifying and characterizing genes that are associated
with susceptibility of complex human diseases. Integration of
different types of data, such as gene expression, genotype variation
and clinical outcomes, can provide more comprehensive information
on a complex disease, and hence can elucidate complex networks of
gene interactions underlying complex traits.
Gene expression data have recently been combined with other
experimental data, such as genotype variation data and clinical data,
to facilitate identiﬁcation of key mechanistic drivers of complex traits
inmice [9,10] and human [11,12]. Oneway to combine gene expression
and genotype variation data is to treat the expression level of a
particular gene as a quantitative trait (so-called expression trait) in
segregating populations, and to map chromosomal regions that
270 E. Lee et al. / Genomics 94 (2009) 269–277control the expression trait. Those genetic regions are called
expression quantitative trait loci (eQTL). This combined technique
could reveal a remarkable wealth of quantitative heritable variation in
the transcriptome, as shown in human and mouse [9,11,12]. However,
the association between gene expression and a disease might be
confounded by the genotype variation, especially when the risk of
disease varies between genotype variations, and expression traits are
also regulated by genotype variations. Due to the number of tests for
eQTL approach, this approach leads to an increased number of false
discoveries. There is one study [13] that demonstrated this problem
and proposed a mixture over markers model that shares information
across both markers and transcripts.
Other integration approaches for combining different types of data
have been proposed [10,13–17]. Firstly, Schadt et al. [10] introduced an
integration methodology to discover key driver of a complex trait by
identifying correlated trait–gene pairs under the inﬂuence of common
genetic loci, then using the genetics to help identify the direction of
causality. The utility of this approach was demonstrated by experi-
mentally validating that three newly identiﬁed causal genes are
involved with the obesity susceptibility. The approach proposed by
Schadt et al. includes multiple steps. First, pair-wise relationships
among genotype variation, gene expression, and a complex trait, are
respectively investigated by identifying quantitative trait loci (QTL)
for the complex trait, selecting gene expression traits correlated with
the complex trait, and detecting expression QTL (eQTL), which overlap
the identiﬁed QTL, for the selected expression traits. In the ﬁnal step,
the likelihood based causality model selection (LCMS) test is used to
identify the causal relationships of the genes detected with over-
lapping loci.
Their ﬁltering step is effective in reducing the large search-space
problem, especially in eQTL search and LCMS testing. However, it
might result in more false negatives than exhaustive searches like our
method, in detecting causal relationships of the genes, especially
when a true causal relationship exists based on the interaction effects
among genotype, gene expression and a trait of interest, but any
pairwise association is weak. It would be partially because there is no
guarantee that the overlapping loci are directly related to those
interaction effects, and hence the approach of Schadt et al. does not
comprehensively handle the interaction effects. Also, they focused on
the causal associations to determine which of the genes causes
disease, rather than responds to the disease state, among many genes
whose expression changes are associated with disease traits.
Secondly, Lan et al. [17] proposed an approach to expose key
components of gene regulatory networks by combining correlation
analysis with linkage mapping. They annotated gene function for
genes whose expressions are highly correlatedwith transcripts, which
has signiﬁcant expression quantitative trait locus/loci (eQTL). How-
ever, they did not discriminate causality relationships among
expression level, genotype and disease. Thirdly, Kendziorski et al.
[13] proposed empirical Bayes Mixture over Markers (MOM) model
that shares information across both markers and transcripts. This
model was proved useful in improving the speciﬁcity of eQTL
identiﬁcations. This work used only genotype variation and gene
expression data rather than disease status or trait data.
More recently, two studies proposed the network based or module
based work, which allowed them to construct a more comprehensive
view of the gene interactions underlying complex traits of interest
[14,16]. Based on Weighted Gene Co-expression Network Analysis
(WGCNA)[15], Presson et al. [14] proposed an approach that
constructs gene sets (modules) from the observed gene expression
data, and then relate them to gene ontology information to study their
biological plausibility. Their work includes steps to identify trait-
module association and trait-related genetic marker association, but it
does not provide the model-based statistical tests that our approach
provides to examine the interaction effects among different types
of data.Note that this approach can alleviate the multiple testing
problems. Another recent work by Chen et al. [16] identiﬁes gene
networks that are perturbed by susceptibility loci and that may in turn
lead to disease. After constructing co-expression network combining
gene expression data and genotype data, they identify sub-networks
that are signiﬁcantly associated with a complex of linked genetic loci
related to disease traits. However, as the above approaches, these two
studies did not consider the interaction effect between two different
data types but our approach provides to examine the interaction
effects among different types of data.
In this study, we developed a two-step procedure to conduct an
integrative analysis of gene expression data, genetic variation data,
and clinical data, which employs the LCMS test. Despite a similarity in
using the same causality models, our approach differs from that of
Schadt et al. in many aspects. We propose to select the most
appropriate causality model for every combination of all SNPs and
all genes proﬁled at the ﬁrst step, based on the LCMS test. In the
following second step, we identify gene expression traits whose
effects on disease (i.e., candidate causal genes) or responses to disease
(i.e., candidate reactive genes) aremodiﬁed by the genotype variation,
by employingmore sophisticated statistical models that correspond to
the causal relationships found in the ﬁrst step. Our integrative
approach has two major advantages. First, the proposed method is
based on an exhaustive search while the Schadt et al.'s method is
based on a non-exhaustive search. In our approach, the exhaustive
investigation on causal relationships of all possible SNP–gene
combinations can avoid false negatives which would result from a
non-exhaustive search. Our approach can hence be more beneﬁcial
when employed in an exploratory (e.g., genome-wide) search, in
which scientists want to identify more hypotheses to be further tested
for biological signiﬁcance. Second, our integrative approach allows
one to examine the interaction effects among different types of data
via the model-based statistical tests and hence to elucidate different
disease susceptibility by identifying both candidate causal and
reactive genes in a more effective and detailed manner. In other
words, the model-based statistical tests enable one to infer both main
and interaction effects via parameter estimation.
Results
The proposed two-step integrative analysis was applied to two CFS
datasets, CFS with NF groups and CFS-MDD/m with NF groups, for
investigating different etiological mechanisms of CFS. We also applied
the multi-step procedure proposed by Schadt et al. [10] to the same
datasets for the purpose of comparison.
Multi-step procedure by Schadt et al.
First, we carried out a gene expression analysis to detect
differentially expressed genes across clinical outcomes We found
that only a few genes are identiﬁed as differentially expressed
(Table 1A) by three commonly used approaches such as the t-test,
signiﬁcance analysis of microarray (SAM) [5] and the Bayesian
regression approach [6]. Second, genotype variation data and clinical
outcomes were analyzed via logistic regression to detect the
susceptibility genes of disease. Out of all 41 markers tested
(Supplementary Table 1), ninemarkers were detected with signiﬁcant
genotype effect on initiation of CFS at a 5% signiﬁcance level, while
only four markers were detected with 5% false discovery rate (FDR
[18]) (Table 1B). Interestingly, different sets of susceptible genes were
identiﬁed as having statistically signiﬁcant association with CFS and
CFS-MDD/m. From the CFS vs. NF comparison, the seven markers in
the NR3C1 gene were identiﬁed as signiﬁcant markers linked to CFS.
On the other hand, the CFS-MDD/m vs. NF comparison revealed the
two signiﬁcant markers in the COMT gene.
Table 1
Parallel analyses for respective association of gene expression and genotype variation with disease status.
Dataset t-test SAM test Bayesian model
A. Number of genes with signiﬁcant change in expression levels over different disease status, which were detected via t-test, SAM test and Bayesian model
CFS vs. NF 1 2 0
CFS-MDD/m vs. NF 1 1 0
Gene SNPa Chromosome Position (Mb)b CFS vs. NFc CFS-MDD/m vs. NFd
B. Signiﬁcant genotype variation linked to disease loci, which were detected via logistic regression
NR3C1e rs2918419 5 142.641 0.0104 0.3950
rs1866388 5 142.702 0.0010f 0.0472
rs860458 5 142.739 0.0104 0.3950
rs852977 5 146.642 0.0035f 0.1878
rs6196 5 146.660 0.0208 0.6423
rs6188 5 146.667 0.0027f 0.0396
rs258750 5 146.674 0.0035f 0.1009
COMTg rs933271 22 18.311 0.0649 0.0025
rs5993882 22 18.317 0.4306 0.0114
As multiple ﬁltering steps in Schadt et al.'s procedure, the separate analyses were conducted respectively on two datasets, CFS vs. NF groups and CFS-MDD/m vs. NF groups.
Bold numbers indicate p-valuesb0.05.
a NCBI dbSNP Build number is 125 using Human Genome Build 35.1.
b Position of SNP on chromosome.
c p-value from logistic regression with CFS vs. NF data.
d p-value from logistic regression with CFS-MDD/m vs. NF data.
e Glucocorticoid receptor located at 5q34.
f Signiﬁcant at the 5% false discovery rate (FDR) [36].
g Catechol-O-methyltransferase located at 22q11.1.
271E. Lee et al. / Genomics 94 (2009) 269–277Finally, for each of the differentially expressed genes across clinical
outcomes, eQTL were searched at each of the markers that were
identiﬁed at the second step, via one-way ANOVA of genotype
variation and gene expression data. We found no signiﬁcant
association between gene expression level and genotype variation
for any genotype–gene expression combination at a 5% signiﬁcant
level. In other words, no signiﬁcant results were detected for both
datasets from the Schadt et al.'s multi-step method.
Two-step integrative analysis
For each combination of 20,160 genes and 41 SNPs, the proposed
integrative analysis was conducted respectively on two datasets, CFS
vs. NF groups and CFS-MDD/m vs. NF groups. For each gene–SNP
combination, the best causal relationship was detected via the
causality model selection at Step 1. In comparing CFS with NF groups,
the reactive model was selected for ∼70% of 20,160 genes on average,
for all nine markers within two known CFS-related genes, such asTable 2
Two-step integration of genotype, gene expression and disease data based on causality mo
Gene SNP CFS vs. NF
Causala Reactiveb Inde
NR3C1d rs2918419 0 (639) 7 (16,215) 0
rs1866388 0 (165) 0 (16,872) 0
rs860458 0 (639) 7 (16,215) 0
rs852977 0 (230) 0 (17,001) 0
rs6196 0 (604) 2 (15,037) 0
rs6188 0 (171) 7 (16,970) 1
rs258750 0 (242) 0 (16,279) 105
COMTe rs933271 0 (1943) 0 (15,156) 0
rs5993882 0 (1022) 0 (14,380) 0
The integrative analyses were conducted respectively on two datasets, CFS vs. NF groups and
two known CFS-related genes (NR3C1 and COMT). For each combination of 20,160 genes and
Numbers in parenthesis indicate the numbers of genes having each causal relationship with
based on one of the three statistical models, corresponding to the detected causal relationsh
corresponding statistical models. Three SNPs, each of which involves signiﬁcant causal rela
a Logistic regression was conducted to identify genes whose expressions have interaction
b Two-way ANOVA was conducted to identify genes whose expressions are affected by in
c Independent test was conducted to identify genes whose expressions differ according t
d Glucocorticoid receptor located at 5q34.
e Catechol-O-methyltransferase located at 22q11.1.NR3C1 and COMT (Table 2). However, in comparing CFS-MDD/mwith
NF groups, the causal model was selected for nearly 70% genes for
threemarkers in the NR3C1 gene. This different tendency in themodel
selection results between CFS and CFS-MDD/mwould imply different
genetic mechanisms of CFS and CFS-MDD/m.
At Step 2, each gene–SNP combination datawas analyzed based on
one of the three statistical models, corresponding to the detected
causal relationship. For all seven SNPs within NR3C1, signiﬁcant causal
relationships with gene expression levels were detected for either or
both datasets (Table 2). Three SNPs (rs258750, rs6188 and rs852977)
showed signiﬁcant relationships with expression levels of a large
number of genes, and can be candidates for geneticmodulators of CFS-
related regulatory pathways. We further conducted pathway enrich-
ment analyses for these three SNPs, and present the results in the next
section. In comparing CFS with NF groups, for the rs258750 marker,
105 genes were identiﬁed with differential expression across
genotypes with 5% FDR from the independent test. This result is
supported by the evidence of the neuroendocrine regulation ofdel selection.
CFS-MDD/m and NF
pendentc Causala Reactiveb Independentc
(3306) 8 (13,955) 3 (5912) 0 (293)
(3123) 15 (4136) 71 (15,976) 0 (48)
(3306) 8 (13,955) 3 (5912) 0 (293)
(2929) 120 (9760) 73 (10,139) 0 (261)
(4519) 0 (16,278) 0 (2013) 0 (1869)
(3019) 52 (2939) 217 (17,074) 0 (147)
(3639) 0 (2769) 14 (12,590) 0 (4801)
(3061) 0 (169) 0 (16,872) 0 (3119)
(4758) 0 (547) 0 (17,333) 0 (2280)
CFS-MDD/mvs. NF groups. Note that the results are presented only for nine SNPs within
41 SNPs, the best causal relationship was detected via causal model selection at Step 1.
each SNP and disease status. At Step 2, each gene–SNP combination data was analyzed
ip. Outside parenthesis, we present the numbers of signiﬁcant genes identiﬁed by the
tionships with expression levels of more than 100 genes, are marked in bold.
effect with genotype variation on disease status.
teraction between genotype variation and disease status.
o SNP genotypes.
Table 3
Signiﬁcantly regulated pathways for SNP rs258750.
Pathwaya Modelb Sourcec Nodesd Gene IDe Gene name
Galactose metabolism Independent KEGG 2/22 B4GALT2 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 2
MGAM Maltase-glucoamylase
Basic mechanisms of SUMOylation Independent BioCarta 1/4 SUMO3 SMT3 suppressor of mif two 3 homolog 3
Internal ribosome entry pathway Independent BioCarta 1/8 EIF4E Eukaryotic translation initiation factor 4E
Neutrophil and its surface molecules Independent BioCarta 1/8 ITGB2 Integrin, beta 2
Alternative complement pathway Independent BioCarta 1/9 CFB Complement factor B
Mechanisms of protein import into the nucleus Independent BioCarta 1/9 NUP62 Nucleoporin 62kDa
Polyadenylation of mRNA Independent BioCarta 1/9 PABP2 Poly(A) binding protein II
B Lymphocyte cell surface molecules Independent BioCarta 1/9 ITGB2 Integrin, beta 2
Adhesion molecules on lymphocyte Independent BioCarta 1/9 ITGB2 Integrin, beta 2
Pathway enrichment analysis was conducted using 105 candidate independent genes, which were identiﬁed for rs258750. Signiﬁcant biological pathways were detected via Fisher's
exact test at a 5% signiﬁcance level. Pathways are listed in order of signiﬁcance, e.g., most signiﬁcant pathway presents at the top.
a Name of biological pathway selected by Fisher's exact test.
b Causality models selected at Step 1.
c Source of pathway: Gene Map Annotator and Pathway Proﬁler (GenMapp), Kyoto Encyclopedia of Genes and Genomics (KEGG) and BioCarta.
d The number of candidate causal/reactive genes associated with pathway/the number of all genes associated with pathway.
e Gene ID of candidate causal/reactive genes associated with pathway.
272 E. Lee et al. / Genomics 94 (2009) 269–277immunity [19], because the gene expression data were obtained from
a mononuclear cell, and the role of glucocorticoid receptor (NR3C1)
gene is to regulate the level of glucocorticoid.
In the integrated analysis for comparing CFS-MDD/m with NF
groups, for the rs6188 marker in the NR3C1 gene, 52 genes showedTable 4
Signiﬁcantly regulated pathways for SNP rs6188.
Pathwaya Modelb Sourcec Nodes
Electron transport chain Causal GenMapp 2/105
Steroid biosynthesis Causal GenMapp 1/9
Blood clotting cascade Causal GenMapp 1/19
FAS signaling pathway (CD95) Causal BioCarta 1/30
Induction of apoptosis through DR3 and DR4/5
Death Receptors
Causal BioCarta 1/32
IL-2 receptor beta chain in T cell activation Causal BioCarta 1/35
HIV-1 Nef: negative effector of FAS and TNF Causal BioCarta 1/57
Agrin in postsynaptic differentiation Reactive BioCarta 3/39
Cell cycle Reactive GenMapp 4/87
Eicosanoid metabolism Reactive BioCarta 2/20
Biosynthesis of cysteine Reactive BioCarta 1/2
Biosynthesis of threonine and methionine Reactive BioCarta 1/2
Inactivation of Gsk3 by AKT causes accumulation
of β-catenin in alveolar macrophages
Reactive BioCarta 2/25
Fatty acid metabolism Reactive KEGG 3/57
Bile acid biosynthesis Reactive KEGG 2/26
Catabolic pathways for methionine, isoleucine,
threonine and valine
Reactive BioCarta 1/4
Basic mechanisms of SUMOylation Reactive BioCarta 1/4
ALK in cardiac myocytes Reactive BioCarta 2/34
Taurine and hypotaurine metabolismf Reactive KEGG 1/5
Biosynthesis of neurotransmittersf Reactive BioCarta 1/6
Pathway enrichment analysis was conducted using 52 candidate causal genes and 217 cand
were detected via Fisher's exact test at a 5% signiﬁcance level. Pathways are listed in order o
the top.
a Name of biological pathway selected by Fisher's exact test.
b Causality models selected at Step 1.
c Source of pathway: Gene Map Annotator and Pathway Proﬁler (GenMapp), Kyoto Ency
d The number of candidate causal/reactive genes associated with pathway/the number o
e Gene ID of candidate causal/reactive genes associated with pathway.
f Pathways with p-value that is slightly larger than 0.05.signiﬁcant interaction effects with the rs6188marker on disease status
CFS-MDD/m from the logistic regression model. Also, the two-way
ANOVA models yielded 217 candidate reactive genes, on which there
are signiﬁcant interaction effects between disease status and
genotypes. Note that these candidate genes, especially reactived Gene IDe Gene name
COX11 Cytochrome c oxidase subunit 11
COX6A1 Cytochrome c oxidase subunit Via polypeptide 1
F13B Coagulation factor XIII, B polypeptide
F13B Coagulation factor XIII, B polypeptide
CFLAR CASP8 and FADD-like apoptosis regulator
CFLAR CASP8 and FADD-like apoptosis regulator
CFLAR CASP8 and FADD-like apoptosis regulator
CFLAR CASP8 and FADD-like apoptosis regulator
UTRN Utrophin
DVL1 Dishevelled, dsh homolog 1
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6
CDC14A CDC14 cell division cycle 14 homolog A
E2F2 E2F transcription factor 2
CDC20 CDC20 cell division cycle 20homolog
PTGES Prostaglandin E synthase
EPHX1 Epoxide hydrolase
CBS Cystathionine-beta-synthase
CBS Cystathionine-beta-synthase
MYD88 Myeloid differentiation primary response gene (88)
DVL1 Dishevelled, dsh homolog 1
HADHB Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme
A thiolase/enoyl-Coenzyme A hydratase, beta subunit
ADH6 Alcohol dehydrogenase 6 (class V)
CYP19A1 Cytochrome P450, family 19, subfamily A, polypeptide 1
HADHB Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme
A thiolase/enoyl-Coenzyme A hydratase, beta subunit
ADH6 Alcohol dehydrogenase 6
CBS Cystathionine-beta-synthase
SMT3H1 SMT3 suppressor of mif two 3 homolog 3
DVL1 Dishevelled, dsh homolog 1
CHRD Chordin
GAD1 Glutamate decarboxylase 1
GAD1 Glutamate decarboxylase 1
idate reactive genes, which were identiﬁed for rs6188. Signiﬁcant biological pathways
f signiﬁcance within each of causality models, e.g., most signiﬁcant pathway presents at
clopedia of Genes and Genomics (KEGG) and BioCarta.
f all genes associated with pathway.
273E. Lee et al. / Genomics 94 (2009) 269–277genes, could not be detected by Schadt et al.'s method. The proposed
two-step integration method revealed the causal association among
gene expression level, genotype and disease status in depth. Candidate
causal/reactive genes were detected also for rs852977 in the NR3C1
gene. However, the candidate gene set for the rs852977 is very similar
to that for the rs6188, with slight differences in causality structure.
This similarity would be due to a strong linkage between the two
SNPs.Pathway enrichment analysis
In comparing CFS with NF groups, we conducted a pathway
enrichment analysis of 105 genes that were identiﬁed to have a
signiﬁcant relationship with the rs258750 marker from the indepen-
dent test at Step 2. The pathway classiﬁcation showed that nine
different pathways were associated with the rs258750 marker at the
5% signiﬁcance level (Table 3). Out of nine pathways, four were
enriched with genes involved in regulation of transcription, transla-
tion or mRNA processing, and three are related with immune system.
In order to compare CFS-MDD/m with NF groups, pathway
enrichment analyses were conducted on the genes that were
identiﬁed to have a signiﬁcant relationship with the rs6188 and/or
rs852977 markers at Step 2. Because of the linkage between the two
SNPs, the results were similar (Tables 4 and 5), and we present herein
details of the results only for the rs6188. While seven different
pathways were detected at the 5% signiﬁcance level for the 52
candidate causal genes, eleven different pathways were detected for
the 217 candidate reactive genes (Table 4). In addition, two other
pathways, whose p-values are slightly larger than the 5% signiﬁcance
level, are listed.
In pathway enrichment analyses of the candidate causal genes, the
steroid biosynthesis pathway appears to have a direct causal effect on
the disease status, CFS-MDD/m, through an integrative action of the
rs6188 marker within the NR3C1 gene. The two signiﬁcantly enriched
biological pathways (i.e., ‘IL-2 Receptor Beta Chain in T cell Activation’,
and ‘HIV-1 Nef: negative effector of FAS and TNF’) are all related to the
immune system. On the other hand, the pathway enrichment analysis
of the candidate reactive genes showed that several pathways related
to lipid metabolism or biosynthesis, such as eicosanoid and fatty acid,
appear to be important for responding to CFS-MDD/m. Furthermore,Table 5
Signiﬁcantly regulated pathways for SNP rs852977.
Pathwaya Modelb Sourcec No
Agrin in postsynaptic differentiation Casual BioCarta 2/
Steroid biosynthesis Casual GenMAPP 1/
Nucleotide GPCRs Casual GenMAPP 1/
RNA polymerase III transcription Casual BioCarta 1/
Blood clotting cascade Casual GenMAPP 1/
Bile acid biosynthesis Casual KEGG 1/
Tyrosine metabolism Casual KEGG 1/
Inactivation of Gsk3 by AKT causes
accumulation of b-catenin in alveolar macrophages
Reactive BioCarta 2/
ALK in cardiac myocytes Reactive BioCarta 2/
Biosynthesis of neurotransmitter Reactive BioCarta 1/
Taurine and hypotaurine metabolism Reactive KEGG 1/
Electron transport chain Reactive GenMAPP 2/
Pathway enrichment analysis was conducted using 120 candidate causal genes and 73 candi
were detected via Fisher's exact test at a 5% signiﬁcance level. Pathways are listed in order o
the top.
a Name of biological pathway selected by Fisher's exact test.
b Causality models selected at Step 1.
c Source of pathway: Gene Map Annotator and Pathway Proﬁler (GenMapp), Kyoto Encyc
d The number of candidate causal/reactive genes associated with pathway/the number o
e Gene ID of candidate causal/reactive genes associated with pathway.other pathways associated with neuron physiology and neurotrans-
mitters appear to respond to CFS-MDD/m.Discussion
We proposed a two-step procedure to integrate gene expression
data, genotype variation data and clinical data, and to identify the
genetic mechanism of a complex disease. We considered three
different statistical tests based on the proposed two-step procedure
for the combined data. For purposes of comparison, two different CFS-
related datasets were analyzed via the multi-step procedure proposed
by Schadt et al. [10] as well as based on our proposedmethod. In these
speciﬁc datasets, no signiﬁcant results were detected from the multi-
step method of Schadt et al., while our method enabled us to identify
many statistically signiﬁcant causal relationships, some of which were
biologically supported by pathway enrichment analyses. These results
demonstrate that our method based on an exhaustive search
investigation would have more power, and motivates us to study the
power of our proposed method via simulations in the future.
Furthermore, our proposed approach provided some interesting
results. First, CFS groups and CFS-MDD/m groups would appear to
have different genotypes and gene expression proﬁles even though
they had the common characteristic of chronic fatigue. In particular,
CFS has major susceptibility markers within the NR3C1 gene, and CFS-
MDD/m seems to have major susceptibility markers within the
catechol-O-methyltransferase (COMT) gene, though they are not
statistically signiﬁcant after FDR correction (Table 1B). The NR3C1
gene regulates the level of glucocorticoid which is the end product of
the hypothalamic-pituitary-adrenal (HPA) whereas COMT catalyzes
the transfer of a methyl group from S-adenosylmethionine to
catecholamines, which is the principal end product of the sympathetic
nervous system (SNS), whose role is maintaining stress-related
homeostasis [20]. The different major susceptibility gene may be
related with to the provoking of MDD/m.
Second, polymorphisms in the glucocorticoid receptor NR3C1 gene
act on CFS and CFS-MDD/m differently. The polymorphisms
(rs258750) within NR3C1 have signiﬁcant effects on CFS, and the
105 gene expression levels independently. However, in the integrated
analysis for comparing CFS-MDD/m and NF groups, polymorphisms
within the NR3C1 gene affect the CFS-MDD/m and several genedesd Gene IDe Gene name
39 DMD Dystrophin
DVL1 Dishevelled, dsh homolog 1
9 F13B Coagulation factor XIII, B polypeptide
10 P2RY4 Pyrimidinergic receptor P2Y, G-protein coupled 4
8 GTF3C1 General transcription factor IIIC, polypeptide 1, alpha 220kDa
19 F13B Coagulation factor XIII, B polypeptide
26 ADH6 Alcohol dehydrogenase 6
37 ADH6 Alcohol dehydrogenase 6
25 MYD88 Myeloid differentiation primary response gene (88)
DVL1 Dishevelled, dsh homolog 1
34 DVL1 Dishevelled, dsh homolog 1
CHRD Chordin
6 GAD1 Glutamate decarboxylase 1
5 GAD1 Glutamate decarboxylase 1
105 COX11 Cytochrome c oxidase subunit 11
COX6A1 Cytochrome c oxidase subunit VIa polypeptide 1
date reactive genes, which were identiﬁed for rs852977. Signiﬁcant biological pathways
f signiﬁcance within each of causality models, e.g., most signiﬁcant pathway presents at
lopedia of Genes and Genomics (KEGG) and BioCarta.
f all genes associated with pathway.
274 E. Lee et al. / Genomics 94 (2009) 269–277expression levels differently. For example, the 217 genes are
differentially expressed according to the rs6188 marker genotype
within NR3C1 and disease status, even though polymorphisms within
NR3C1 have no direct signiﬁcant effects after FDR correction on the
CFS-MDD/m. In addition, the 52 genes also regulate the CFS-MDD/m,
through integrated actionwith the rs6188marker. The different action
of the NR3C1 gene on gene expression level and disease may be an
outcome of other factors, such as environmental effects or poly-
morphisms of the COMT gene. The catecholamines which are
regulated by the COMT gene, have been often been regarded as
immunosuppressive [20].
Two pathway enrichment analyses for the 52 candidate causal
genes and 217 candidate reactive genes indicated that our approach
can recover plausible regulatory mechanisms of CFS-MDD/m by
comparing CFS-MDD/m and NF groups. From the comparison, we
noticed that the pathways related to the immune system and steroid
may have causal effect on disease state through an integrative action
of the NR3C1 gene. Both the NR3C1 gene that regulates the level of
glucocorticoid, and the steroid that includes corticosteroids are
known to regulate the immune function [19]. A number of studies
have foundmany irregularities in the immune systems in CFS patients
[21]. This suggested that an important cause of CFS-MDD/mwould be
the immune system dysfunction, regulated by the neuroendocrine
system, which rs6188 in the NR3C1 gene seems inﬂuence. Another
potential implication of this comparison is that the CFS-MDD/m
status and genetic polymorphisms can jointly induce different
activation and expression of several lipid related metabolisms, neuron
physiology differentiation, and neurotransmitters. Our results can be
supported by the known relationship between eicosanoid or fatty acid
and CFS [22–25].
However, since fatigue is a core symptom in major depressive
disorder [26], CFS-MDD/m patients might have fatigue due to the
depression rather than unexplained causes, and hence the signiﬁcant
results may be related to a ‘major depression disorder with
melancholic features’ rather than chronic fatigue. For example, the
excessive hypothalamus-pituitary-adrenal (HPA) axis responses, of
which end products are glucocorticoids, are known to be hallmarks of
depression [27–29]. Also, the major depression can be associated with
the immune activation, dysfunction of neurotransmitters at synapse
[30–32], and essential fatty acids [33].
Our integrative analyses considering the interaction effect among
different levels of data could elucidate different disease susceptibility
and differentially expressed genes of genetically different individuals.
Some results showed that integrating genotype and expression data
may help the search for new directions for the treatment of common
human diseases that are not being detected using only one type of
data. The integrated analysis provided more information than the two
separate analyses of gene expression data and genotype variation data
for characterizing CFS that has several possible causes.
In conclusion, our approach to the integration of heterogeneous
data sets can be generally applied to other studies in which gene
expression data, genotype variation data and clinical data are
available, and it can be very useful as the importance of integrated
data analysis has been increasing. The proposed approach can also be
extended to datasets containing other type of data, such as protein
data rather than clinical data. Our approach can be readily applicable
to quantitative traits rather than binary clinical outcome traits, by
employing linear regression analysis. Also, it can be easily applied to
genome-wide association studies, and can handle environmental
factors, such as age and sex, by treating these factors as covariates in
the regression model. Furthermore, our approach can be extended to
the gene-set approach, the module based approach or co-expression
network as Presson et al. [14] and Chen et al. [16] did.
However, there are some limitations to the proposedmethod. First,
the causality models, which we assumed herein, are too simple to
represent true mechanisms, which would be more complicated due topossible interactions between causal-reactive genes [10]. Further
considerations for more complicated models are necessary in order to
identify the genetic mechanism of complex diseases. Second, the
proposed approach may need large computing although it is
applicable to genome-wide studies because it is not limited in the
scale of data. Another limitation would be a misclassiﬁcation problem
in that the proposedmethod relies on the LCMS. Our current approach
does not use FDR procedure to account for the model misclassiﬁcation
problem. In fact, FDR procedurewas employed only in the second step,
not in the ﬁrst step for the model selection procedure that chooses the
model with the minimum AIC among the three causal models. While
anticipating the problem, we still employed the LCMS process because
it showed good power for detecting true models in the simulation
evaluated by Schadt et al. [10]. Our approach can be extended to
account for the errors caused by the model misclassiﬁcation in the
ﬁrst step. For example, we can test for the difference in the AIC values
of three causality models, because the chance for model misclassiﬁca-
tion would be high when the difference between the smallest AIC
value from the selected model and those from the other models is not
large. A permutation-based nonparametric test might be developed
for this testing. We think it requires a further study to control
simultaneously two types of errors: causality model selection, and
signiﬁcant maker-gene pair identiﬁcation. Finally, we plan to address
the multiplicity problem for tests with (tightly) linked markers,
although we used a FDR procedure for lack of standard methods that
deal with multiplicity among dependent tests.Methods
Chronic fatigue syndrome (CFS) dataset
Chronic fatigue syndrome (CFS) is a debilitating illness lacking
consistent anatomic lesions and eluding conventional laboratory
diagnosis. CFS has no conﬁrmatory physical signs or laboratory
abnormalities, and its etiology and pathophysiology are unknown.
This disease characterized by severe chronic fatigue, lasting at least
6 months, which is accompanied by symptoms such as impairment in
short-term memory or concentration, sore throat, tender lymph
nodes, and muscle pain [34]. The CDC Chronic Fatigue Syndrome
Research Group produced the dataset for 173 patients including gene
expression, proteomic, single nucleotide polymorphism (SNP), and
clinical data, and the dataset is available to the public online (http://
www.camda.duke.edu/camda06/datasets/index.html).
The CAMDA 2006 competition datasets were used for the analysis
in this study. The patients include 34 males and 137 females, and the
majority race is white. According to severity of symptoms, the patients
were classiﬁed into ﬁve groups of CFS. In this study, we only consider
three groups: 46 patients meeting the CFS research case deﬁnition
(CFS), 19 patients meeting the CFS research case deﬁnition and having
‘a major depressive disorder with melancholic features’ (CFS-MDD/
m), and 36 patients who show no fatigue (NF).
This CFS data set has been analyzed by many research groups for
identifyingmolecularmarkers and elucidating pathophysiology of CFS
[35], for ﬁnding two differentially expressed genes related with
fatigue and depression, respectively [36–38], for discriminating
classes of unexplained chronic fatigue based on differential gene
expressions [39,40], and for examining the relationship between CFS
and allostatic load based on the clinical dataset [41–46]. In the CFS
dataset, the expression levels of 20,160 genes were assessed from
peripheral blood mononuclear cells, via custom-printed single-
channel oligonucleotide chips. We conducted quantile normalization
[47] on the gene expression data which were pre-processed by the
original CDC research group. For genotype data, the whole blood DNA
was extracted and speciﬁc areas of the genes of interest were
ampliﬁed by PCR [48–51].
Fig. 1. Flow diagram to illustrate two-step integration procedure based on causal
relationship. In the ﬁrst step, for each gene expression-genetic variation combination,
the most appropriate causality models are selected to understand the direction of the
causal relationship among genetic variation, gene expression level, and disease. In the
second step, signiﬁcance testing is carried out based on a statistical model for each
combination, such as logistic regression and a two-way analysis of variance (ANOVA),
according to the causality model selected from the ﬁrst step.
Fig. 2. Possible causal relationships amongmRNA level, genotype variation and complex
disease proposed by Schadt et al. [10]. SNP represents genotype variation, mRNA
indicates the expression level of a gene, and disease represents a phenotype of interest,
such as a complex disease. Three possible simplest causal relationships are represented,
given that mRNA and disease are somehow under the control of a common SNP.
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A two-step procedure was developed to integrate gene expression,
genotype data and clinical data, and thus to elucidate mechanisms
underlying disease susceptibility and progression. In Fig. 1, a ﬂow
diagram is presented to illustrate the integration method based on
causal relationship among the three different levels of data. In the ﬁrst
step, the most appropriate causality models are selected to under-
stand the direction of the causal relationship among genetic variation,
gene expression level, and disease for each gene expression-genetic
variation combination. In the second step, signiﬁcance testing is
carried out based on a statistical model for each combination, such as
logistic regression and a two-way analysis of variance (ANOVA),
according to the causality model selected from the ﬁrst step. Via these
tests, we identify gene expression traits whose effects on disease
status or responses to disease status are modiﬁed by the genotype
variation effects.
Step 1: Causality model selection
The possible causal relationships among genetic variation, gene
expression level and disease trait can be represented by graphical
models [10]. Three simple models, such as causal, reactive and
independent models, are illustrated in Fig. 2. In this study, we assume
that each pair of genetic locus and expressed gene has one of these
three simple causal relationships, according to which we build
statistical models to examine potential relationships among the
gene expression level, genotype variation and disease status. In
order to ﬁnd the most possible causal relationship among the three
heterogeneous data, we adapted the likelihood based causality model
selection (LCMS) test [10], which uses conditional correlation
measures for determining the relationships best supported by the
data. First, likelihoods associated with each of the causality models are
constructed and maximized with respect to the model parameters.
Second, the best model is selected for each SNP-transcript combina-
tion, by using Akaike Information Criterion (AIC [52]) which can be
used to compare different models.
Assuming standard Markov properties for the simple graphs, the
joint probability distributions for the three models are as follows:
• Causal Model: P (S, R, D)=P (S) P (R|S) P (D|R)
• Reactive Model: P (S, R, D)=P (S) P (D|S) P (R|D)
• Independent Model: P (S, R, D)=P (S) P (R|S) P (D|R, S)
Here S represents a genotype variation, R gene expression, and D
disease status. P(S) is the genotype probability distribution for marker
S and is further assumed to be co-dominant. P(R|S) and P(R|D) are the
conditional probabilities of R given genotypes S and disease status D,
respectively. In an application to the CFS data, we further assume that
the random variable R is conditionally normally distributed, and the
random variable D has a binomial distribution. Therefore, in
probability P(D|R), the randomvariable D has a binominal distribution
with a success probability that can bemodelled by a logistic regressionmodel. P(D|S) is the probability distribution of D conditional on locus
S, in which the random variable D also has a binomial distribution.
Based on these assumptions, the likelihood of a correspondence to
each of the joint probability distributions is constructed. For each
model, the model parameters are estimated via a standard maximum
likelihood method. The best model supported by the data is chosen
based on the AIC, which is commonly used to compare models with
different numbers of parameters.
Step 2: Statistical tests for identifying candidate causal and reactive
genes
In Step 2, we perform statistical tests to determine the signiﬁcance
of the genetic regulatory relationships described in the causality
model that are selected at Step 1. The determination of response and
independent variables in the statistical models depend on the
causality model selected at Step 1. These statistical tests allow us to
consider the interaction effects among the three different levels of
data and to elucidate differences in disease susceptibility and gene
expression pattern across genetically different individuals. The two-
step procedure results in a set of candidate causal and reactive genes,
whose expressions affect disease status and respond to disease status
under the inﬂuence of genotype variation, respectively.
Test for causal model
In order to investigate gene expression traits whose effects on
disease status are modiﬁed by genotype variation, we examine the
interaction effect of genotype variation and gene expression level on
the disease status using logistic regression below:
log it πð Þ = S + R + S × R; ð1Þ
where π represents the probability of getting the disease; S represents
the effect of genotype variation such as SNPs; R represents the effect
of gene expression levels; and S×R represents the interaction effect
between genotype variation and gene expression level.
Test for reactive model
For investigating gene expression traits whose responses to
disease status are affected by genotype variations, we ﬁt the following
two-way ANOVA model with the interaction between genotype
variation and disease groups:
R = S + D + S × D; ð2Þ
where S represents the effect of genotype variation; D represents the
effect of disease groups; and S×D represents the interaction effect
between genotype variation and disease groups.
Test for independent model
When the independent model is selected at Step 1, the effect of
genotype variation on each of gene expression and disease can be
276 E. Lee et al. / Genomics 94 (2009) 269–277investigated separately. First, the logistic regression is employed to
detect genotypic markers linked to disease loci:
log it πð Þ = S ð3Þ
Next, we identify genotypic markers that regulate gene expression
levels, based on the one-way ANOVA model where the dependent
variable is R and the independent variable is S.
Detecting signiﬁcance of association via multiple testing adjustment
In the Step 2, signiﬁcant associations among genotype variation,
gene expression and disease are declared via statistical tests for all
possible pairs of gene expression-genotype variation. Due to the large
number of tests, the multiple testing problem needs to be addressed.
In order to adjust this multiplicity, we used a step-up procedure
controlling false discovery rate (FDR [18]) of 5%.
Pathway enrichment analysis
Pathway enrichment analysis was performed on each of the
candidate causal/reactive gene sets selected from two-step procedure
to identify ‘signiﬁcantly regulated pathways’ which are deﬁned as
signiﬁcantly over-presentedpathways for a particular gene set.Weused
the pathway annotations in Gene Map Annotator and Pathway Proﬁler
(GenMapp) [53], Kyoto Encyclopaedia of Genes and Genomics (KEGG)
[54], and BioCarta (http://www.biocarta.com/) when employing soft-
ware called ArrayXPath (http://www.snubi.org/software/ArrayXPath/)
[55] for the pathway enrichment analysis. This study involves
comparing ‘the proportion of genes in a speciﬁc pathway’ among a
list of differentially regulated genes detected from our two-step
integration to that among all genes in a database. For the comparison,
the association between a particular pathway and a speciﬁc list of genes
is tested by constructing a 2×2 contingency table. For the statistical
signiﬁcance of pathway enrichments, p-values were calculated by the
Fisher's exact test [56] based on a hypergeometric distribution. Note
that this approach has beenwidely used in functional interpretation of
gene expression data analysis using gene ontology (GO) enrichment
analysis [57,58] and pathway enrichment analysis [59,60].
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